27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
There is consistent evidence supporting an association between AF and increased incidence of dementia in patients with stroke whereas there remains considerable uncertainty about any link in the broader population. 5 key findings →
Design: meta-analysis Participants: 46,637 Evidence: high
Full summary, score breakdown and related studies → Original source
AF is independently associated with increased risk of dementia. 5 key findings →
Design: meta-analysis Participants: 77,668 Evidence: high
Full summary, score breakdown and related studies → Original source
Hypertension significantly increases the risk of vascular dementia. 4 key findings →
Design: meta-analysis Participants: 768 Evidence: high
Full summary, score breakdown and related studies → Original source
This study found that long-term exposure to air pollution was associated with a higher risk of dementia. 2 key findings →
Design: cohort study Participants: 4,590 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Statin users were less likely to have incident dementia/cognitive impairment without dementia during a 5-year follow-up. 2 key findings →
Design: cohort study Participants: 1,674 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Depression is an accepted risk factor for dementia, but it is unclear if this relationship is causal. 3 key findings →
Design: longitudinal study Participants: 388 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 11 601 participants (mean [SD] age, 59.18 [9.41] years; 5569 male [48.0%]), 9145 (78.8%) were exposed to at least 1 ACE indicator, 4241 (36.6%) to at least 1 AAE indicator, and 3531 (30.4%) to both ACE and AAE markers. 5 key findings →
Design: cohort study Participants: 601 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Incident AF was associated with an increased risk of dementia, independent of clinical stroke in an elderly population. 5 key findings →
Design: longitudinal study Participants: 435 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Diabetes mellitus did not increase the risk of incident AD in the Framingham cohort overall; however, DM may be a risk factor for AD in the absence of other known major AD risk factors. 3 key findings →
Design: cohort study Participants: 2,210 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Atherosclerosis of the intracranial arteries is an independent and important risk factor for dementia, suggesting potentially reversible pathways unrelated to Alzheimer pathology and stroke through which vascular changes may influence dementia risk. 2 key findings →
Design: longitudinal study Participants: 200 Evidence: moderate
Full summary, score breakdown and related studies → Original source
People with raised systolic blood pressure (≥160 mm Hg) or high serum cholesterol concentration (≥6.5 mmol/l) in midlife had a significantly higher risk of Alzheimer's disease in later life, even after adjustment for age, body mass index, education, vascular events, smoking status, and alcohol consumption, than those with normal systolic blood pressure (odds ratio 2.3, 95% confidence interval 1.0 to 5.5) or serum cholesterol (odds ratio 2.1, 1.0 to 4.4). 5 key findings →
Participants: 1,449 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We included 147,986 participants (Chinese [n = 6,034], Filipino [n = 4,649], Japanese [n = 3,099], South Asian [n = 996], non-Latino White [n = 133,208]); the mean baseline age ranged from 69 to 72 years, and the percentage of female participants ranged from 40% to 63% across groups. 5 key findings →
Design: cohort study Participants: 6,034 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After propensity score matching, each group consisted of 15901 patients. 5 key findings →
Design: cohort study Participants: 15,901 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Consumption of up to three servings of wine daily is associated with a lower risk of AD in elderly individuals without the APOE epsilon-4 allele. 5 key findings →
Design: cohort study Participants: 260 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94). 5 key findings →
Design: cohort study Participants: 39,665 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Older people with diabetes receiving metformin have slower cognitive decline and lower dementia risk. 5 key findings →
Participants: 1,037 Evidence: high
Full summary, score breakdown and related studies → Original source
In ARIC (n = 1,736, mean age 63, 58.8% female, 48.7% non-Hispanic White individuals, median follow-up 18.6 years), the dementia incidence rate was 10.4 (95% CI, 9.2-11.6) per 1,000 person-years. 5 key findings →
Design: cohort study Participants: 1,736 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
People with severe mental illnesses (SMIs), including schizophrenia spectrum disorders (SSD), major depressive disorder (MDD), and bipolar disorder (BD), experience elevated rates of physical comorbidity and premature mortality. 3 key findings →
Design: cross-sectional Participants: 694,086 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 2,335 participants (mean age 52.3 ± 11.2 years; 56.6% women), CVD risk trajectories over 10 years were classified as accelerated increase (29.2%), moderate increase (30.9%), or stable (39.9%). 5 key findings →
Design: cohort study Participants: 2,335 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Uncontrolled diabetes increases the risk of Alzheimer's disease and VaD. 4 key findings →
Participants: 1,248 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the Research Article "Magnitude and Time-Course of Dementia Risk in Stroke Survivors: A Population-Wide Matched Cohort Study" by Joundi et al., 1 the keys for Figure 3, A-D should indicate red for "Stroke," "Ischemic Stroke," "ICH," and "Stroke," respectively. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this large cohort, heavy smoking in midlife was associated with a greater than 100% increase in risk of dementia, AD, and VaD more than 2 decades later. 5 key findings →
Participants: 5,367 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Out of 462,327 eligible participants, those with constipation were associated with higher incidence of three outcome diseases (1415/20,263 [7.0%]) than those without (18,848/442,064 [4.3%]), with adjusted hazard ratio (HR) being 1.35 [1.27-1.42]. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our results confirm that vitamin D deficiency is associated with a substantially increased risk of all-cause dementia and Alzheimer disease. 5 key findings →
Participants: 171 Evidence: low
Full summary, score breakdown and related studies → Original source
Central auditory dysfunction is a precursor to AD. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →